GlassScriptPhysician profile
Derek B Berberian
NPI 1346597200
$9,370.14
in general payments reported to CMS, 2019-2025
34 companies · $2,401 in 2025
The $2,401 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $695 · 2020: $543 · 2021: $747 · 2022: $1,082 · 2023: $2,087 · 2024: $1,817 · 2025: $2,401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,303.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,528.87 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Alkermes, INC. | $782.30 | 2021-2025 | Lybalvi, Aristada |
| Supernus Pharmaceuticals, INC. | $778.69 | 2021-2025 | Qelbree, Qelbree, Xyosted |
| Intra-Sana Laboratories | $775.72 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Takeda Pharmaceuticals U.S.A., INC. | $738.43 | 2019-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $693.58 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $516.19 | 2020-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $429.86 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Tris Pharma INC | $400.17 | 2023-2025 | Dyanavel Xr |
| Allergan, INC. | $349.79 | 2019-2020 | |
| Axsome Therapeutics, INC. | $346.43 | 2022-2025 | Auvelity |
| Lundbeck LLC | $334.64 | 2019-2024 | Rexulti |
| Novo Nordisk INC | $230.33 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Corium, LLC | $218.04 | 2022-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $212.80 | 2019-2024 | Ingrezza |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $201.18 | 2022-2025 | Loreev Xr, Sertraline Hcl |
| Vanda Pharmaceuticals INC. | $128.86 | 2024-2025 | Fanapt, Hetlioz |
| Pfizer INC. | $107.78 | 2023-2025 | |
| Antares Pharma, INC. | $98.88 | 2023-2025 | Xyosted, Nocdurna, Tlando |
| Lilly USA, LLC | $75.92 | 2025 | Zepbound |
| Halozyme INC | $51.28 | 2023 | |
| Janssen Pharmaceuticals, INC | $45.84 | 2022-2023 | Spravato |
| Ironshore Pharmaceuticals INC. | $44.88 | 2023 | Jornay Pm |
| Avanir Pharmaceuticals, INC. | $41.78 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $37.81 | 2019 | |
| Neuronetics, INC. | $32.47 | 2023-2024 | Neurostar Tms Therapy System |
| Adlon Therapeutics L.P. | $29.68 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.81 | 2022 | |
| Vertical Pharmaceuticals, LLC | $26.74 | 2019 | |
| Sunovion Pharmaceuticals INC. | $17.94 | 2022 | |
| Bausch Health US, LLC | $17.26 | 2022 | |
| Collegium Pharmaceutical, INC. | $16.70 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $16.34 | 2022 | |
| Noven Therapeutics, LLC | $15.15 | 2024 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Berberian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.